Furthermore, in comparison with IgG pretreatment, anti–PDGF-B pretreatment reduced hPASMC migration with IPAH or SSc-PAH macrophage-conditioned medium by approximately 40%–50%. Here, PDGFB is linked to systemic sclerosis.